Sanofi and Regeneron expand immunology partnership to the tune of $8bn
Having already brought one of the most successful drugs in the world to market, Sanofi and Regeneron are broadening their…
01 Oct 2026
Varda pockets $251m to back space-based pharma processing mission
Varda Space Industries has banked $251m in a Series D financing to scale its in-space pharmaceutical processing operations, as the industry increasingly recognises the potential of producing drugs in microgravity…
01 Oct 2026
Bristol Myers Squibb secures expanded US approval for Camzyos
The US Food and Drug Administration (FDA) has expanded the approved indication for Bristol Myers Squibb’s (BMS) Camzyos (mavacamten) to treat symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adults and paediatric…
01 Oct 2026
BioMarin and Profluent partner on AI-designed enzyme therapies
BioMarin Pharmaceutical has entered a research collaboration with Profluent to design and optimise novel enzyme therapies for its drug development pipeline. Under the agreement, Profluent will deploy its proprietary suite…
30 Sep 2026
Atossa plans shareholder stake in potential PRV proceeds
Atossa Therapeutics has put in place a plan that would give its shareholders a share of any proceeds from the use or sale of a priority review voucher (PRV). PRVs…
30 Sep 2026
OBIO marks $704m funding milestone for Canadian health tech ventures
Life sciences and technology companies supported by the Ontario Bioscience Innovation Organization’s (OBIO) Capital Access Advisory Program (CAAP) have collectively raised more than C$1bn ($704.7m) in capital. The initiative is…
30 Sep 2026
Kyowa Kirin, Knight agree Latin American distribution deal for mogamulizumab
Kyowa Kirin’s wholly owned subsidiary Kyowa Kirin International has signed an exclusive distribution agreement with Knight Therapeutics for Poteligeo (mogamulizumab) across selected Latin American markets. Under the terms of the…